Aplicable disease
Download
1 / 27

Aplicable Disease - PowerPoint PPT Presentation


  • 91 Views
  • Uploaded on

Aplicable Disease. World Health Organization 1997. Atherosclerosis and its consequences (ASPVD, ASCAD, ASCVD) and Cancer together are responsible for over 80% of ALL deaths in industrialized countries. “Cardiovascular Drug Therapy”1996. Metal Toxicity & Heart Disease.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Aplicable Disease' - nadine


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

World health organization 1997
World Health Organization 1997

  • Atherosclerosis and its consequences (ASPVD, ASCAD, ASCVD) and Cancer together are responsible for over 80% of ALL deaths in industrialized countries



Metal toxicity heart disease
Metal Toxicity & Heart Disease

  • Chapter 175 MagnesiumEDTA chelation Martin Rubin PhD

  • EDTA acts as an anti-oxidant, anti-coagulant and decalcifies deposits.

  • 30 infusions of EDTA in a patient 14 years post MI and multi-vessel CABG. Ultrafast CT scan showed 216 calcified lesions and total calcium score of 15872. Post chelation: 118 lesions, calcium score 7970

Martin Rubin PhD


Metal toxicity heart disease1
Metal Toxicity & Heart Disease

  • “EDTA chelation has an implicit advantage in that it can favorably influence all facets of the (atherosclerotic) disease development. Thus it can also provide an alternative to the combination of drugs administered to obtain a multiplicity of therapeutic effects.”

Prof. Martin Rubin



Metal toxicity heart disease3
Metal Toxicity & Heart Disease

Idiopathic Dilated Cardiomyopathy

  • Hg – 22,000 x normal

  • Sb – 12,000 x normal

  • Au – 11 x normal

  • Cr – 13 x normal

  • Co – 4 x normal

Journal of American College of Cardiology, 1999



Metal toxicity pvd1
Metal Toxicity & PVD

  • 79 year old woman - Presenting History

  • 1979 NIDDM and hypertension

  • 1992 Mastectomy for breast carcinoma

  • 1993 Increasing PVD

  • 1996 Left hemiplegia CVA

  • 1997 March - Severe pain in left foot at rest. Hospitalized but refused angiogram and possible amputation. Started chelation. Medications: Minidiab, Adalat, Quinine sulphate, Warfarin



Metal toxicity pvd2
Metal Toxicity & PVD chelation.

  • 3 blinded controlled trials

    • Olszewer and Carter—10 patients crossover

    • Van Rij—32 patients, slight improvement, one major outlier

    • Guldagger—51% vs. 24% improved

      • Underpowered, 1/3 dropout

      • Statistical problems

      • Patients continued to smoke

      • Did not follow the standard protocol as claimed


Metal toxicity vascular disease
Metal Toxicity & Vascular Disease chelation.

Multi-Centered Trial

  • 220 patients with documented vascular disease

  • Received chelation with three year follow-up

  • No deaths or MIs, 4 minor strokes

  • Symptoms improved

  • Chappell, Mitchell, Born, Ventresco, Hancke, Olszewer, van der Schaar, Blaha


Metal toxicity vascular disease1
Metal Toxicity & Vascular Disease chelation.

Multi-Centered Trial

  • Compared to conventional therapies

    • Expected 31/220 angioplasties, we had 2

    • Expected 16/220 CABG, we had 6

    • Expected 15/220 MI’s, we had none

    • Expected 6/220 deaths, we had none

    • Of 185 patients with symptoms, 68% had a complete resolution


Metal toxicity mi
Metal Toxicity & MI chelation.

  • Improved myocardial perfusion in patients with advanced ischemic heart disease with an integrative management program including EDTA metal binding therapy.

Ali M, et al. J Integrative Med.1997;1:7-112


Metal toxicity mi1
Metal Toxicity & MI chelation.

  • Comparative study of pre- and post-chelation myocardial thallium perfusion scans showed clear, objective evidence of significant improvement in myocardial perfusion in five of six patients in whom such studies were performed


Metal toxicity heart disease4
Metal Toxicity & Heart Disease chelation.

  • EDTA Chelation Therapy in Myocardial Stunning and Hibernation. Edwards D, et al. J.Adv.Med 1997;10,4:233-257

  • 5 Case Reports

  • All patients were studied using first-pass radionuclide ventriculography (RNV) All ejection fractions improved


Metal toxicity heart disease5
Metal Toxicity & Heart Disease chelation.

  • Conclusion: EDTA Metal Binding Therapy clearly and convincingly reverses the condition of myocardial hibernation and possibly stunning


Metal toxicity angina
Metal Toxicity & ANGINA chelation.

  • Kitchell and Meltzer-- small controlled trial, and 71% of 38 patients with disabling angina improved symptoms and exercise capacity

  • Hancke and Flytlie—69% of 253 patients improved EKG and exercise capacity, 91% of 207 patients on NTG stopped it, 58/65 on waiting list for Bypass avoided surgery


Metal toxicity angina1
Metal Toxicity & ANGINA chelation.

  • Casdorph 16/18 improved ejection fractions

  • Clarke 16/20 patients assymptomatic after chelation

  • Olszewer and Carter 844 patients, 77% marked improvement, 16% good improvement


Metal toxicity autism
Metal Toxicity & Autism chelation.

Important Issues of:

  • Blood Brain Barrier

  • Protein Structure

  • Total Mercury Reservoir


Metal toxicity autism1
Metal Toxicity & Autism chelation.

Retrospective Study

  • 31 patients with diagnosis:

  • Autism

  • Autism Like Spectrum

  • Pervasive Developmental Delay


Metal toxicity autism2
Metal Toxicity & Autism chelation.

Key To Success - Protocol

  • Trans Dermal DMPS (TD-DMPS)

  • 4 : 1 Ratio of GSH : DMPS

  • Conjugated with amino acids,

  • Delivered in a micro-encapsulated liposomal phospholipid base


Metal toxicity autism3
Metal Toxicity & Autism chelation.

Retrospective Study

  • Baseline

  • 2 months

  • 4 months

  • 6 months

  • 8 months

  • 10 months

  • 12 months

  • then 4 months


Metal toxicity autism4
Metal Toxicity & Autism chelation.

Retrospective Study

  • All 31 patients tested:

  • Urine Metal Toxicity & Essentials

  • Hair Metal Toxicity & Essentials

  • RBC Metal Toxicity

  • Fecal Metal Toxicity


Metal toxicity autism5
Metal Toxicity & Autism chelation.

Retrospective Study

  • All 31 patients showed LITTLE or NO level of mercury on initial baseline test results


ad